MARKSANS logo

Marksans Pharma Limited Stock Price

NSEI:MARKSANS Community·₹111.6b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 34 Fair Values set on narratives written by author

MARKSANS Share Price Performance

₹246.19
-8.96 (-3.51%)
₹216.67
Fair Value
₹246.19
-8.96 (-3.51%)
13.6% overvalued intrinsic discount
₹216.67
Fair Value
Price ₹246.19
AnalystConsensusTarget ₹216.67

MARKSANS Community Narratives

·
Fair Value ₹216.67 13.6% overvalued intrinsic discount

Developed Markets Will Support Affordable Generic Expansion

0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
₹216.67
13.6% overvalued intrinsic discount
Revenue
12.02% p.a.
Profit Margin
16.01%
Future PE
23.21x
Price in 2028
₹310.53

Trending Discussion

Updated Narratives

MARKSANS logo

MARKSANS: Upcoming Board Meeting And UK Regulatory Success Will Drive Momentum

Fair Value: ₹216.67 13.6% overvalued intrinsic discount
18 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet average dividend payer.

1 Risk
4 Rewards

Marksans Pharma Limited Key Details

₹29.5b

Revenue

₹12.8b

Cost of Revenue

₹16.7b

Gross Profit

₹12.6b

Other Expenses

₹4.2b

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
9.22
56.72%
14.16%
1.0%
View Full Analysis

About MARKSANS

Founded
1992
Employees
1840
CEO
Mark Saldanha
WebsiteView website
marksanspharma.com

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally. The company offers products in the pain management, cardiovascular, central nervous system, anti-diabetic, gastrointestinal, analgesics, upper respiratory, ear care, skincare, anticancer, anti-ulcerative, anti-allergy, antiviral, dietary, cardiac, dermatology, antihistamines, anti-fungal, anti-viral, laxatives, and cold and cough therapeutic areas. Its product portfolio includes plain, enteric-coated, and film coated tablets; soft gelatin and hard capsules; oral liquids; and ointments, as well as creams and liquids. The company provides its products to supermarkets, high street retailers, pharmacy chains, and wholesalers. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Recent MARKSANS News & Updates

Analysis Article May 29

Earnings Beat: Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Marksans Pharma Limited ( NSE:MARKSANS ) defied analyst predictions to release its full-year results, which were ahead...
Analysis Article May 28

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Recent updates

No updates